FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213089059> ?p ?o ?g. }

• W4213089059 abstract "Abstract Background Inflammatory bowel disease (IBD) treatment paradigms recommend objective disease activity assessment and reactive therapeutic drug monitoring (TDM) prior to changes in biologic therapy. We aimed to describe objective marker and TDM assessment in routine clinical practice prior to biologic therapeutic changes in adult IBD patients. Methods TARGET-IBD is a prospective longitudinal cohort of over 2100 IBD patients receiving usual care at 34 US academic or community centers enrolled between June 2017 and October 2019 who received biologic therapy and had a dose change or biologic discontinuation for lack of efficacy. Objective markers of disease activity within 12 weeks prior included fecal calprotectin, C-reactive protein (CRP), endoscopy, computed tomography (CT) and magnetic resonance imaging (MRI). TDM data for infliximab or adalimumab was obtained. Results 525 patients (71.4% Crohn’s disease [CD], 28.6% ulcerative colitis [UC]) receiving biologic therapy underwent dose change (55.6%) or discontinuation (44.4%) for lack of efficacy. The majority were Caucasian (85.7%), 18–39 years old (52.2%), privately insured (81.5%), and at academic centers (73.7%). For dose changes, 67.5% had at least one objective disease activity assessment or TDM in the 12 weeks prior (CD 67.9%, UC 66.2%; P = 0.79). The most common objective marker was CRP in both CD (39.1%) and UC (54.5%). CRP and calprotectin were used significantly more in UC ( P = 0.02 and P = 0.03). TDM was obtained in 30.7% (28.8% UC, 31.4% CD; P = 0.72) prior to dose change. For biologic discontinuation, 79.4% patients underwent objective assessment or TDM prior. In CD, CRP (46.3%) was most common, and CT ( P = 0.03) and MRI ( P < 0.001) were significantly more frequent than in UC. TDM was performed in 40.1% of patients (43.5% UC, 38.0% CD, P = 0.49) prior to discontinuation. Among all participants with dose change or discontinuation, endoscopy was performed in 29.3% with CD and 31.3% with UC. Academic care setting was associated with objective assessment before therapy change (OR 1.59, 95% CI 1.01–2.50). Conclusion Nearly one-third of patients undergoing a biologic dose change or discontinuation do not undergo objective disease activity assessment or TDM. Assessment choice differs by disease. Future studies assessing the impact of such practices on long-term outcomes are needed." @default.
• W4213089059 created "2022-02-24" @default.
• W4213089059 creator A5016847503 @default.
• W4213089059 creator A5017140014 @default.
• W4213089059 creator A5019801327 @default.
• W4213089059 creator A5049169459 @default.
• W4213089059 creator A5051304369 @default.
• W4213089059 creator A5054313028 @default.
• W4213089059 creator A5055932714 @default.
• W4213089059 creator A5062617621 @default.
• W4213089059 creator A5071230912 @default.
• W4213089059 creator A5078565829 @default.
• W4213089059 creator A5082987648 @default.
• W4213089059 date "2022-02-19" @default.
• W4213089059 modified "2023-10-10" @default.
• W4213089059 title "Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD" @default.
• W4213089059 cites W1012814869 @default.
• W4213089059 cites W1967714899 @default.
• W4213089059 cites W1995734769 @default.
• W4213089059 cites W2003835888 @default.
• W4213089059 cites W2014291261 @default.
• W4213089059 cites W2034939253 @default.
• W4213089059 cites W2038017077 @default.
• W4213089059 cites W2046106520 @default.
• W4213089059 cites W2048453651 @default.
• W4213089059 cites W2052724916 @default.
• W4213089059 cites W2077187057 @default.
• W4213089059 cites W2077531651 @default.
• W4213089059 cites W2088135039 @default.
• W4213089059 cites W2123352987 @default.
• W4213089059 cites W2162805528 @default.
• W4213089059 cites W2529215786 @default.
• W4213089059 cites W2611548364 @default.
• W4213089059 cites W2744879509 @default.
• W4213089059 cites W2766230215 @default.
• W4213089059 cites W2778397807 @default.
• W4213089059 cites W2781482422 @default.
• W4213089059 cites W2794595980 @default.
• W4213089059 cites W2809296974 @default.
• W4213089059 cites W2897263984 @default.
• W4213089059 cites W2911374625 @default.
• W4213089059 cites W2923576761 @default.
• W4213089059 cites W2942891315 @default.
• W4213089059 cites W2979463093 @default.
• W4213089059 cites W2979970083 @default.
• W4213089059 cites W3161874086 @default.
• W4213089059 cites W4205253993 @default.
• W4213089059 cites W4233817719 @default.
• W4213089059 doi "https://doi.org/10.1186/s12876-022-02143-x" @default.
• W4213089059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35183108" @default.
• W4213089059 hasPublicationYear "2022" @default.
• W4213089059 type Work @default.
• W4213089059 citedByCount "2" @default.
• W4213089059 countsByYear W42130890592023 @default.
• W4213089059 crossrefType "journal-article" @default.
• W4213089059 hasAuthorship W4213089059A5016847503 @default.
• W4213089059 hasAuthorship W4213089059A5017140014 @default.
• W4213089059 hasAuthorship W4213089059A5019801327 @default.
• W4213089059 hasAuthorship W4213089059A5049169459 @default.
• W4213089059 hasAuthorship W4213089059A5051304369 @default.
• W4213089059 hasAuthorship W4213089059A5054313028 @default.
• W4213089059 hasAuthorship W4213089059A5055932714 @default.
• W4213089059 hasAuthorship W4213089059A5062617621 @default.
• W4213089059 hasAuthorship W4213089059A5071230912 @default.
• W4213089059 hasAuthorship W4213089059A5078565829 @default.
• W4213089059 hasAuthorship W4213089059A5082987648 @default.
• W4213089059 hasBestOaLocation W42130890591 @default.
• W4213089059 hasConcept C112705442 @default.
• W4213089059 hasConcept C126322002 @default.
• W4213089059 hasConcept C188816634 @default.
• W4213089059 hasConcept C2776207728 @default.
• W4213089059 hasConcept C2777138892 @default.
• W4213089059 hasConcept C2778260677 @default.
• W4213089059 hasConcept C2778292693 @default.
• W4213089059 hasConcept C2778715236 @default.
• W4213089059 hasConcept C2779008522 @default.
• W4213089059 hasConcept C2779134260 @default.
• W4213089059 hasConcept C2779280984 @default.
• W4213089059 hasConcept C2780132546 @default.
• W4213089059 hasConcept C2780272996 @default.
• W4213089059 hasConcept C2780479503 @default.
• W4213089059 hasConcept C41260117 @default.
• W4213089059 hasConcept C71924100 @default.
• W4213089059 hasConcept C90924648 @default.
• W4213089059 hasConceptScore W4213089059C112705442 @default.
• W4213089059 hasConceptScore W4213089059C126322002 @default.
• W4213089059 hasConceptScore W4213089059C188816634 @default.
• W4213089059 hasConceptScore W4213089059C2776207728 @default.
• W4213089059 hasConceptScore W4213089059C2777138892 @default.
• W4213089059 hasConceptScore W4213089059C2778260677 @default.
• W4213089059 hasConceptScore W4213089059C2778292693 @default.
• W4213089059 hasConceptScore W4213089059C2778715236 @default.
• W4213089059 hasConceptScore W4213089059C2779008522 @default.
• W4213089059 hasConceptScore W4213089059C2779134260 @default.
• W4213089059 hasConceptScore W4213089059C2779280984 @default.
• W4213089059 hasConceptScore W4213089059C2780132546 @default.
• W4213089059 hasConceptScore W4213089059C2780272996 @default.
• W4213089059 hasConceptScore W4213089059C2780479503 @default.
• W4213089059 hasConceptScore W4213089059C41260117 @default.
• W4213089059 hasConceptScore W4213089059C71924100 @default.

• next